1. Search Result
Search Result
Results for "

S. aureus

" in MCE Product Catalog:

128

Inhibitors & Agonists

1

Fluorescent Dye

9

Peptides

20

Natural
Products

25

Recombinant Proteins

13

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-107222
    Lysionotin

    Others Inflammation/Immunology
    Lysionotin is a flavonoid isolated from few flower lysionotus herbs. Lysionotin efficiently inhibit α-Toxin (a pore-forming protein) expression and shows significant protection against S. aureus in vitro and in vivo. Lysionotin has the potential for the treatment of S. aureus induced pneumonia.
  • HY-14926
    Levonadifloxacin

    (S)-(-)-Nadifloxacin; WCK 771

    Antibiotic Bacterial Infection
    Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes.
  • HY-146458
    Antibacterial agent 102

    Bacterial Cytochrome P450 Infection
    Antibacterial agent 102 (compound 32) possesses potent in vitro and in vivo antibacterial activity, with MICs < 0.5 μg/mL in Staphylococcus aureus (S. aureus). Antibacterial agent 102 also moderately inhibits CYP3A4 with an IC50 value of 6.148 μM. Antibacterial agent 102 can reduce Methicillin-resistant Staphylococcus aureus (MRSA) load in thigh infected mice.
  • HY-146591
    Antibacterial agent 87

    Bacterial Infection
    Antibacterial agent 87 (Compound 4h) is a potent antibacterial agent with MIC values of 0.125, 0.0625 and 0.0625 μg/mL against MRSA, MRSE and S. aureus, respectively.
  • HY-146403
    Antibacterial agent 98

    Bacterial Infection
    Antibacterial agent 98 (compound g37) is a potent and orally active antibacterial agent. Antibacterial agent 98 inhibits the ATPase activity of Gyrase B and impairs Staphylococcus aureus (S. aureus ) DNA supercoiling. Antibacterial agent 98 shows antibacterial activity and not induce resistance development of MRSA (methicillin-resistant S. aureus).
  • HY-146503
    Antibacterial agent 86

    Others Infection
    Antibacterial agent 86 (Compound A11) is the most active and displays bacteriostatic activities against methicillin-resistant S. aureus, with MIC values as low as 0.00191 μg/mL, which is 162 and 32 times lower than that of the marketed antibiotics tiamulin and retapamulin, respectively.
  • HY-N1673
    2,5-Dihydroxybenzaldehyde

    Gentisaldehyde

    Bacterial Infection
    2,5-Dihydroxybenzaldehyde (Gentisaldehyde) is a naturally occurring antimicrobial that inhibits the growth of Mycobacterium avium subsp. paratuberculosis. 2,5-Dihydroxybenzaldehyde is active against S. aureus strains with a MIC50 of 500 mg/L.
  • HY-146593
    Antibacterial agent 88

    Bacterial Infection
    Antibacterial agent 88 (Compound 5h) is a potent antibacterial agent with MIC values of both ≤0.0156 μg/mL against MRSA, MRSE and S. aureus. Antibacterial agent 88 also inhibits B. subtilis with an MIC of 4 μg/mL.
  • HY-N2417
    Stearyl glycyrrhetinate

    Bacterial Infection
    Stearyl glycyrrhetinate, a major component in licorice extract, has a MIC against S. aureus strains of more than 256 mg/L. Stearyl glycyrrhetinate has antibacterial effects.
  • HY-B0975
    Penicillin V Potassium

    Phenoxymethylpenicillin potassium salt

    Bacterial Antibiotic Infection
    Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis.
  • HY-B0536A
    Clinafloxacin hydrochloride

    AM 1091 hydrochloride; CI 960 hydrochloride; PD127391 hydrochloride

    Bacterial Antibiotic Infection
    Clinafloxacin hydrochloride (AM 1091 hydrochloride) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro. Clinafloxacin hydrochloride is against DNA gyrase and topoisomerase IV of S. aureus with IC50 values of 0.92 µg/ml and 1.62 µg/ml, respectively.
  • HY-B0536
    Clinafloxacin

    AM-1091; CI-960; PD 127391

    Bacterial Antibiotic Infection
    Clinafloxacin (AM 1091) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro. Clinafloxacin is against DNA gyrase and topoisomerase IV of S. aureus with IC50 values of 0.92 µg/ml and 1.62 µg/ml, respectively.
  • HY-B0466A
    Cloxacillin

    Antibiotic Bacterial Cancer Infection Inflammation/Immunology
    Cloxacillin is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 µM. Cloxacillin can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins.
  • HY-B0466
    Cloxacillin sodium monohydrate

    Bacterial Antibiotic Infection Inflammation/Immunology Cancer
    Cloxacillin sodium monohydrate is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 µM. Cloxacillin sodium monohydrate can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins.
  • HY-B0466B
    Cloxacillin sodium

    Bacterial Antibiotic Infection Inflammation/Immunology Cancer
    Cloxacillin sodium is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 µM. Cloxacillin sodium can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins.
  • HY-B0097
    Floxuridine

    5-Fluorouracil 2'-deoxyriboside

    Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis Cancer Infection
    Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis. Floxuridine has antiviral effects against HSV and CMV.
  • HY-147522
    ADG-2e

    Bacterial Antibiotic Infection Cancer
    ADG-2e is a potent antibacterial agent with MICs of 16, 4, 2, and 2 μg/mL for E. coli [KCTC 1682], P. aeruginosa [KCTC 1637], B.subtilis [KCTC 3068], and S. aureus [KCTC 1621], respectively. ADG-2e shows anti-metastatic activity against breast cancer cells.
  • HY-10581A
    Gatifloxacin hydrochloride

    AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
  • HY-10581B
    Gatifloxacin mesylate

    AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.
  • HY-10581
    Gatifloxacin

    AM-1155; BMS-206584; PD135432

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml). Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
  • HY-10581C
    Gatifloxacin sesquihydrate

    AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate

    Bacterial Topoisomerase Antibiotic Infection Inflammation/Immunology
    Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.
  • HY-P3349
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal]

    Bacterial Infection
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal] (Compound 9C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 25 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively.
  • HY-P3348
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip]

    Bacterial Infection
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip] (Compound 8C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 12.5 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively.
  • HY-B1256A
    Cefuroxime

    Bacterial Antibiotic Infection
    Cefuroxime is an orally active second-generation cephalosporin antibiotic with increased stability to β-lactamase. Cefuroxime has a broad spectrum activity against Gram-positive and Gram-negative bacteria.
  • HY-B1256
    Cefuroxime sodium

    Bacterial Antibiotic Infection
    Cefuroxime sodium is an orally active second-generation cephalosporin antibiotic with increased stability to β-lactamase. Cefuroxime sodium has a broad spectrum activity against Gram-positive and Gram-negative bacteria.
  • HY-16115
    BPH-652

    Others Metabolic Disease
    BPH-652 is a S. aureus dehydrosqualene synthase (CrtM) inhibitor, with a Ki of 1.5 nM and an IC50 of 100-300 nM (S. aureus pigment formation).
  • HY-18702
    Targocil

    Bacterial Infection
    Targocil functions as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) with MIC90s of 2 μg/ mL for both MRSA and MSSA.
  • HY-133119
    PK150

    Bacterial Infection
    PK150, an analogue of Sorafenib, shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 µM, respectively.
  • HY-N5127
    Nonacosane

    Bacterial Infection
    Nonacosane, isolated from Baphia massaiensis, exhibits weak activities against E. coli, B. subtilis, P. aeruginosa and S. aureus.
  • HY-128916
    dmDNA31

    Bacterial Infection
    dmDNA31 is a rifamycin-class antibiotic that inhibits bacterial DNA-dependent RNA polymerase with potent bactericidal activity against S. aureus.
  • HY-151567
    Antibacterial agent 123

    Bacterial Infection
    Antibacterial agent 123 (compound 111) is a potent membrane-disrupting agent to combat antibiotic-resistant Gram-positive bacteria.
  • HY-151403
    Antimicrobial agent-9

    Bacterial Infection
    Antimicrobial agent-9 (Compound 16) is an antimicrobial agent with an MIC range of 4-8 μg/mL against gram-positive and gram-negative bacteria. Antimicrobial agent-9 also shows anti-inflammatory activity.
  • HY-151400
    Antimicrobial agent-6

    Bacterial Infection
    Antimicrobial agent-6 (Compound 11) is an antimicrobial agent with a MIC range of 4-8 μg/mL against gram-positive and gram-negative bacteria. Antimicrobial agent-6 also shows anti-inflammatory activity.
  • HY-120659
    Gly-Gly-AMC

    Others Others
    Gly-Gly-AMC is a fluorogenic peptide substrate. Gly-Gly-AMC can be used to assess bacterial protease activity of P. aeruginosa and S. aureus.
  • HY-N8186
    (3R)-7,4’-Dihydrohomoisoflavanone

    Bacterial Infection
    (3R)-7,4’-Dihydrohomoisoflavanone is a natural product with antibacterial activities against S. aureus and methicillin-resistant Staphylococcus aureus (MRSA).
  • HY-N6908
    Continentalic acid

    Bacterial Cancer Infection Inflammation/Immunology
    Continentalic acid from Aralia continentalis has minimum inhibitory concentrations (MICs) of approximately 8-16 µg/mL against S. aureus, including the Methicillin (HY-121544) susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) standard strains.
  • HY-103645
    GW779439X

    Bacterial Aurora Kinase Apoptosis Cancer Infection
    GW779439X is a pyrazolopyridazine identified in an inhibitor of the S. aureus PASTA kinase Stk1. GW779439X potentiates the activity of β-lactam antibiotics against various MRSA and MSSA isolates, some even crossing the breakpoint from resistant to sensitive. GW779439X is an AURKA inhibitor and induces apoptosis by the caspases 3/7 pathway. MRSA:methicillin-resistant S. aureus; MSSA: methicillin-sensitive S. aureus
  • HY-17460A
    Garenoxacin Mesylate hydrate

    BMS284756 Mesylate hydrate

    Bacterial Topoisomerase DNA/RNA Synthesis Antibiotic Infection
    Garenoxacin (BMS284756) Mesylate hydrate is an orally active quinolone antibiotic and has a broad spectrum of activity against a wide array of gram-positive and gram-negative bacteria, anaerobes, and fastidious organisms.
  • HY-17460
    Garenoxacin

    BMS284756

    Bacterial Topoisomerase DNA/RNA Synthesis Antibiotic Infection
    Garenoxacin (BMS284756) is an orally active quinolone antibiotic and has a broad spectrum of activity against a wide array of gram-positive and gram-negative bacteria, anaerobes, and fastidious organisms.
  • HY-146428
    Anti-MRSA agent 4

    Bacterial Infection
    Anti-MRSA agent 4 (compound 7a) is a potent and selective growth inhibitor of Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA), with MIC ≤ 0.26 µM. Anti-MRSA agent 4 exhibits no cytotoxic and no hemolytic activity in HEK293 cells.
  • HY-115658
    VU0420373

    Bacterial Infection Metabolic Disease
    VU0420373 is a potent heme sensor system (HssRS) activator with an EC50 of 10.7 μM and a pEC50 of 4.97. VU0420373 induces heme biosynthesis, and is toxic to fermenting S. aureus.
  • HY-N8151
    Sanguisorbigenin

    Bacterial Infection
    Sanguisorbigenin is a natural antibacterial agent that inhibits methicillin-resistant S. aureus (MRSA).
  • HY-N1453
    Hypocrellin B

    Apoptosis Fungal Parasite Cancer Infection
    Hypocrellin B, a pigment isolated from the fungi Hypocrella bambusae and Shiraia bambusicola, is an apoptosis inducer. Hypocrellin B can be used as a photosensitizer for photodynamic therapy of cancer. Hypocrellin B also has antimicrobial and antileishmanial activities.
  • HY-124138
    Pikromycin

    Albomycetin; Amaromycin

    Antibiotic Bacterial Infection
    Pikromycin is a macrolide antibiotic that has been found in S. venezuelae and active against E. coli, S. aureus and B. subtilis.
  • HY-138621
    Antibacterial agent 19

    Bacterial Infection
    Antibacterial agent 19 (compound 8) is a potent antibacterial agent. Antibacterial agent 19 has antibacterial activity against K. pneumoniae, (M-R)S. aureus and (M-R,V-R)S. aureus with MIC values of 0.022, 0.022 and 0.045 mg/mL, respectively.
  • HY-146400
    Antibacterial agent 97

    Bacterial Infection
    Antibacterial agent 97 (hit compound) is a potent antibacterial agent. Antibacterial agent 97 shows antibacterial activities with MIC of 16 and 16 µg/mL for Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus), respectively.
  • HY-Y0366
    Lauric acid

    Endogenous Metabolite Bacterial Infection
    Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
  • HY-N7010
    (-)-Corynoxidine

    Cholinesterase (ChE) Bacterial Infection
    (-)-Corynoxidine is an acetylcholinesterase inhibitor with an IC50 value of 89.0 μM, isolated from the aerial parts of Corydalis speciosa. (-)-Corynoxidine exhibits antibacterial activities against Staphylococcus aureus and methicillin-resistant S. aureus strains in different degrees.
  • HY-B0132S
    Norfloxacin-d5

    Bacterial Antibiotic Infection
    Norfloxacin-d5 is a deuterium labeled Norfloxacin. Norfloxacin is a fluoroquinolone antibiotic that inhibits the growth of Gram-positive and Gram-negative bacteria (MICs = 4 μg/mL and 1 μg/mL for S. aureus and P. aeruginosa, respectively). Norfloxacin also inhibits the growth S. pseudintermedius, S. aureus, E. coli, Pasturella, and S. canis isolates from dogs (mean MIC50s = 0.25 μg/mL, 1 μg/mL, 0.03 μg/mL, 1 μg/mL, and 1 μg/mL, respectively).
  • HY-112240
    Antibacterial agent 104

    Bacterial Antibiotic Infection
    Antibacterial agent 104 (Compound 7) is a potent antibacterial agent. Antibacterial agent 104 displays excellent antibacterial activity in vitro and good efficacy in vivo against MRSA.
  • HY-19906
    LFF-571

    Bacterial Antibiotic Infection
    LFF-571 is an orally active semisynthetic thiopeptide antibiotic. LFF-571 shows potent activity against a Clostridium difficile and Staphylococcus aureus with MIC values of 0.03 and 0.125 μg/mL, respectively. LFF-571 can be used for the research of infection.
  • HY-144822
    Anti-MRSA agent 2

    Bacterial Infection
    Anti-MRSA agent 2 (compound 14) has highly inhibitory activity against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.098 μg/ml, and relatively low cytotoxicity in normal cells. Anti-MRSA agent 2 has strong ability to destroy bacterial membrane and bind to genomic DNA.
  • HY-18169
    MUT056399

    Fab-001

    Bacterial Infection
    MUT056399 (Fab-001) is a highly potent inhibitor of the FabI enzyme of both S. aureus and E. coli with 50% inhibitory concentration IC50s of 12 nM and 58 nM, respectively.
  • HY-101479
    Iclaprim

    AR-100

    Bacterial Antibiotic Infection
    Iclaprim is a new selective bacterial Dihydrofolate inhibitor, which can inhibit the growth of S. aureus (MRSA) with an MIC90 of 0.06 μg/mL.
  • HY-Y0366S5
    Lauric acid-d5

    Endogenous Metabolite Bacterial
    Lauric acid-d5 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
  • HY-Y0366S3
    Lauric acid-d3

    Endogenous Metabolite Bacterial Infection
    Lauric acid-d3 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
  • HY-Y0366S2
    Lauric acid-d2

    Endogenous Metabolite Bacterial
    Lauric acid-d2 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
  • HY-Y0366S1
    Lauric acid-d23

    Endogenous Metabolite Bacterial Infection
    Lauric acid-d23 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
  • HY-N1312
    Sinapaldehyde

    Bacterial Infection
    Sinapaldehyde exhibits moderate antibacterial against Methicillin resistant S. aureus (MRSA) and E. coli with MIC values of 128 and 128 μg/mL.
  • HY-146460
    Antimicrobial agent-2

    Reactive Oxygen Species Infection
    Antimicrobial agent-2 (compound V-a) is a broad-spectrum antimicrobial agent, possessing inhibitory activity against various Gram-positive and -negative bacteria. Antimicrobial agent-2 has excellent inhibitory effect on Methicillin-resistant Staphylococcus aureus (MRSA) with a MIC of 1 μg/mL. Antimicrobial agent-2 can effectively damage the membrane and lead to the leakage of protein, also can induce the generation of ROS. Antimicrobial agent-2 exhibits low toxicity, no obvious resistance and good bioavailability.
  • HY-147988
    DNA Gyrase-IN-5

    DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-5 (Compound 8I-w) is a potent DNA gyrase inhibitor with an IC50 of 0.10 μM. DNA Gyrase-IN-5 shows antibacterial activities against wild type and drug-resistant strains.
  • HY-Y0366S
    Lauric acid-13C

    Endogenous Metabolite Bacterial Infection
    Lauric acid-13C is the 13C labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
  • HY-P2312
    Human β-defensin-3

    HβD-3

    Antibiotic Bacterial Infection
    Human β-defensin-3 (HβD-3) is an antibiotic anti-microbial peptide produced by epithelial cells with antimicrobial activities and reduces the effect of inflammatory cytokine responses. Human β-defensin-3 is against different microbes with IC90 values of 6-25 μg/ml.
  • HY-Y0366S4
    Lauric acid-13C-1

    Endogenous Metabolite Bacterial Cardiovascular Disease
    Lauric acid-13C-1 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
  • HY-131989
    Desacetylcephapirin sodium

    Deacetylcephapirin sodium

    Bacterial Antibiotic Infection
    Desacetylcephapirin sodium (Deacetylcephapirin sodium) is an active metabolite of Cephapirin (HY-A0153A). Desacetylcephapirin sodium has antimicrobial against S. aureus and coagulase-negative staphylococci mastitis pathogen.
  • HY-B0975A
    Penicillin V

    Phenoxymethylpenicillin

    Antibiotic Bacterial Infection
    Penicillin V (Phenoxymethylpenicillin) is a potent and orally active antibiotic. Penicillin V shows antibacterial activity for Streptococci, Clostridium difficile and staphylococcus aureus. Penicillin V has the potential for the research of otitis, sinusitis, pharyngitis and tonsillitis.
  • HY-147958
    Antibacterial agent 113

    Bacterial Infection
    Antibacterial agent 113 (compound 3) is a potent antibacterial agent. Antibacterial agent 113 shows antibacterial activity against P.aeruginosa, S.mutans, B.subtilis, E.coli, E.faecalis, S.typhimuriumand, and S.aureus microorganisms, with MIC values all of 156.25 μM.
  • HY-A0279
    Pristinamycin

    Pristinamycine

    Bacterial Antibiotic Infection
    Pristinamycin, produced by Streptomyces pristinaespiralis, is an orally active streptogramin-like antibiotic consisting of two chemically unrelated components: Pristinamycin I (PI) and Pristinamycin II (PII). Pristinamycin is highly active against many antibiotic-resistant pathogens, particularly Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA) and Enterococcus faecium (VREF).
  • HY-N10572
    Antibacterial synergist 2

    Bacterial Infection
    Antibacterial synergist 2 (compound 27) is a biofilm inhibitor. Antibacterial synergist 2 shows inhibitory effects to S. enterica, S. aureus, P. aeruginosa and C. albicans. Antibacterial synergist 2 can be used for the research related to biofilm-forming pathogens.
  • HY-118946
    BPH-1358

    NSC50460

    Bacterial Cancer Infection
    BPH-1358 (NSC50460) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC50s of 1.8 μM and 110 nM, respectively, and is active against S. aureus in vitro (MIC ~250 ng/mL).
  • HY-145265
    Antimicrobial photosensitizer-1

    Bacterial Infection
    Antimicrobial photosensitizer-1 is a promising candidate as the antimicrobial photosensitizer for combating pathogenic microorganism infections. Antimicrobial photosensitizer-1 exhibits an impressive antimicrobial efficacy in S. aureus-infected mice wounds.
  • HY-147959
    Antibacterial agent 114

    Bacterial Infection
    Antibacterial agent 114 (compound 1) is a potent antibacterial agent. Antibacterial agent 114 shows antibacterial activity against P.aeruginosa, B.subtilis, E.coli, E.faecalis, S.typhimuriumand, S.mutans, and S.aureus microorganisms, with MIC values of 625, 625, 625, 625, 625, 1250 and 1250 μM, respectively.
  • HY-147957
    Antibacterial agent 112

    Bacterial Infection
    Antibacterial agent 112 (compound 2) is a potent antibacterial agent. Antibacterial agent 112 shows antibacterial activity against P.aeruginosa, S.mutans, B.subtilis, E.coli, E.faecalis, S.typhimuriumand, and S.aureus microorganisms, with MIC values of 625, 625, 1250, 1250, 1250, 1250 and 1250 μM, respectively.
  • HY-16487
    Temafloxacin

    TMFX; TA-167 free acid; A-62254 free acid

    Bacterial Antibiotic Infection
    Temafloxacin (TMFX) is an orally active quinolone broad-spectrum antibacterial agent. Temafloxacin is well tolerated in lower respiratory and genitourinary tract infections.
  • HY-14956
    Nemonoxacin

    TG-873870

    Antibiotic Bacterial Infection Inflammation/Immunology
    Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia.
  • HY-113595
    Temafloxacin hydrochloride

    TMFX hydrochloride; TA-167; A-62254

    Antibiotic Bacterial Infection
    Temafloxacin (TMFX) hydrochloride is an orally active quinolone broad-spectrum antibacterial agent. Temafloxacin hydrochloride is well tolerated in lower respiratory and genitourinary tract infections.
  • HY-130613
    MAC-545496

    Bacterial Infection
    MAC-545496 is a nanomolar inhibitor of glycopeptide-resistance-associated protein R (GraR). MAC-545496 displays strong binding affinity to the full-length GraR protein (Kd ≤ 0.1 nM). MAC-545496 is an antivirulence agent that reverses β-lactam resistance in Methicillin-resistant strains (MRSA).
  • HY-144823
    Anti-MRSA agent 3

    Bacterial Infection
    Anti-MRSA agent 3 (compound 18) has highly inhibitory activity against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.098 μg/ml, and low cytotoxicity in normal cells. Anti-MRSA agent 3 has relatively strong ability to destroy bacterial cell wall and membrane, high binding affinity to bacterial genomic DNA.
  • HY-147999
    GlcN-6-P Synthase-IN-1

    Bacterial Fungal Cytochrome P450 Infection
    GlcN-6-P Synthase-IN-1 (Compound 4d) is a Glucosamine-6-phosphate (GlcN-6-P) synthase inhibitor with an IC50 of 3.47 μM. GlcN-6-P Synthase-IN-1 exhibits significant antimicrobial activity. GlcN-6-P Synthase-IN-1 has good penetration in the CNS and is able to inhibit the cytochrome P450, CYP3A4 isoform.
  • HY-146133
    LA-Bac8c

    Bacterial Antibiotic Infection
    LA-Bac8c is a Lipoic acid modified antimicrobial peptide with enhanced antimicrobial properties. LA-Bac8c inhibits S. aureus, MRSA, S. epidermidis, E. coli, and P. aeruginosa with MICs of 1, 4, 8, 8, and 8 μg/mL.
  • HY-118946B
    BPH-1358 mesylate

    NSC50460 mesylate

    Bacterial Cancer Infection
    BPH-1358 mesylate (NSC50460 mesylate) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC50s of 1.8 μM and 110 nM, respectively. BPH-1358 mesylate is active against S. aureus in vitro (MIC ~250 ng/mL).
  • HY-N0802
    Tenuigenin

    Senegenin

    NF-κB Bacterial Infection Inflammation/Immunology
    Tenuigenin is a major active component isolated from the root of the Chinese herb Polygala tenuifolia. Tenuigenin protects against S.aureus-induced pneumonia by inhibiting NF-κB activation. Tenuigenin has anti-inflammatory effect.
  • HY-118946A
    BPH-1358 free base

    NSC50460 free base

    Bacterial Cancer Infection
    BPH-1358 free base (NSC50460 free base) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC50s of 1.8 μM and 110 nM, respectively, and is active against S. aureus in vitro (MIC ~250 ng/mL).
  • HY-W039169
    4-Chloroguaiacol

    4-Chloro-2-methoxyphenol

    Bacterial Infection
    4-Chloroguaiaco (4-Chloro-2-methoxyphenol) is a phenol derivative, with antimicrobial activity. 4-Chloroguaiaco shows inhibition against S. aureus and E. coli with MICs of both 110 μg/mL.
  • HY-P3078
    Amphomycin

    Bacterial Antibiotic Infection
    Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci.
  • HY-119123
    Voxvoganan

    LTX-109

    Fungal Bacterial Infection
    Voxvoganan (LTX-109), a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan can be used for the research of bacterial skin infections, fungal infections and nasal decolonisation of MRSA.
  • HY-146722
    Antibacterial agent 89

    Bacterial DNA/RNA Synthesis Infection
    Antibacterial agent 89 is a potent antibacterial agent. Antibacterial agent 89 shows anti-clostridial activity. Antibacterial agent 89 inhibits the release of cytotoxins and the β’CH-σ interaction. Antibacterial agent 89 disrupts the process of bacterial transcription.
  • HY-B0364A
    Dyclonine hydrochloride

    Dyclocaine hydrochloride

    Bacterial Fungal Aldehyde Dehydrogenase (ALDH) Cancer Infection
    Dyclonine (Dyclocaine) hydrochloride is an orally effective ALDH covalent inhibitor (crosses blood-brain barrier), with an IC50 of 35 µM for ALDH2 and 76 µM for ALDH3A1. Dyclonine hydrochloride has sensitizing activities for targeted cancer cells and antibacterial. Dyclonine hydrochloride is also a local anesthetic that blocks the transmission of various nerve impulses or stimuli and inhibits the sensation of touch and pain.
  • HY-150044
    Type II topoisomerase inhibitor 1

    DNA/RNA Synthesis Topoisomerase Bacterial Infection
    Type II topoisomerase inhibitor 1 is a potent and selective E. coli DNA gyrase inhibitor (IC50: 1.7 nM), and forms hydrogen bonds with Asp73 residue. Type II topoisomerase inhibitor 1 inhibits topoisomerase IV activity (IC50: 0.98 μM). Type II topoisomerase inhibitor 1 can be used in the research of antibacterial area.
  • HY-151373
    MurA-IN-2

    Bacterial Infection
    MurA-IN-2 (compound 37), a chloroacetamide fragment containing a primary aliphatic amine, is a potent MurA inhibitor with an IC50 value of 39  μM. MurA-IN-2 has antibacterial activity and inhibits the bacterial cell wall synthesis.
  • HY-10979
    AN0128

    Bacterial Infection Inflammation/Immunology
    AN0128 is a boron-containing antibacterial and anti-inflammatory agent. AN0128 against S. aureus, S. epidermidis, P. acnes, B. subtilis with minimum inhibitory concentration (MIC) values of 1, 0.5, 0.3, 1 μg/mL. AN0128 can be used for the research of periodontal disease and cutaneous diseases.
  • HY-P1978
    CysHHC10

    Bacterial Infection
    CysHHC10 is a synthetic antimicrobial peptide (AMP), and exhibits strong anti-microbial properties against both Gram-positive and Gram-negative bacteria. The MIC values of CysHHC10 against E. coli, P. aeruginosa, S. aureus and S. epidermidis are 10.1 mM, 20.2 mM, 2.5 mM and 1.3 mM, respectively.
  • HY-101479S
    Iclaprim-d6

    Bacterial Antibiotic Infection
    Iclaprim-d6 (AR-100-d6) is the deuterium labeled Iclaprim. Iclaprim is a new selective bacterial Dihydrofolate inhibitor, which can inhibit the growth of S. aureus (MRSA) with an MIC90 of 0.06 μg/mL.
  • HY-17586
    Dalbavancin hydrochloride

    MDL-63397 hydrochloride; BI-397 hydrochloride

    Bacterial Antibiotic Infection
    Dalbavancin hydrochloride (MDL-63397 hydrochloride) is a semisynthetic lipoglycopeptide antibiotic with potent bactericidal activity against Gram-positive bacteria. Dalbavancin hydrochloride inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg/mL and 0.25 μg/mL, respectively.
  • HY-17586A
    Dalbavancin

    MDL-63397; BI-397

    Bacterial Antibiotic Infection
    Dalbavancin (MDL-63397) is a semisynthetic lipoglycopeptide antibiotic with potent bactericidal activity against Gram-positive bacteria. Dalbavancin inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg/mL and 0.25 μg/mL, respectively.
  • HY-127146
    Platensimycin

    Antibiotic Bacterial
    Platensimycin is an antibiotic produced by S. platensis that inhibits gram-positive bacteria by selectively inhibiting cellular lipid biosynthesis (IC50=0.1 μM). Platensimycin targets the β-ketoacyl-acyl-carrier-protein synthase I/II, FabF/B, an enzyme that participates in the biosynthesis of fatty acids (IC50s=48 nM and 160 nM for S.aureus and E.coli enzymes, respectively). Platensimycin is a promising agent for overcoming antibiotic resistance.
  • HY-17593
    Solithromycin

    CEM-101; OP-1068

    Bacterial Antibiotic Infection
    Solithromycin (CEM-101) is an orally bioavailable, effective antimicrobial agent, with IC50s for inhibition of cell viability, protein synthesis, and growth rate are 7.5 ng/mL, 40 ng/mL, and 125 ng/mL for Streptococcus pneumonia, Staphylococcus aureus, and Haemophilus influenzae, respectively. Solithromycin binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis.
  • HY-125733
    Thiocillin I

    Bacterial Antibiotic Infection
    Thiocillin I is a thiopeptide antibiotic and has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Thiocillin I against S. aureus 1974149, E. faecalis 1674621, B. subtilis ATCC 6633 and S. pyogenes 1744264 are 2 μg/mL, 0.5 μg/mL, 4 μg/mL and 0.5 μg/mL, respectively.
  • HY-P1978A
    CysHHC10 TFA

    Bacterial Infection
    CysHHC10 TFA is a synthetic antimicrobial peptide (AMP), and exhibits strong anti-microbial properties against both Gram-positive and Gram-negative bacteria. The MIC values of CysHHC10 TFA against E. coli, P. aeruginosa, S. aureus and S. epidermidis are 10.1 mM, 20.2 mM, 2.5 mM and 1.3 mM, respectively.
  • HY-17647
    Zoliflodacin

    ETX0914; AZD0914

    DNA/RNA Synthesis Bacterial Antibiotic Infection
    Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. Zoliflodacin has potent in vitro antibacterial activity against Gram-positive and Gram-negative organisms, including S. aureus with the MIC90 of 0.25 μg/mL.
  • HY-143292
    Antibacterial agent 81

    Bacterial Infection
    Antibacterial agent 81 is a DNA transcription inhibitor. Antibacterial agent 81 inhibits S. aureus USA300 and M. smegmatis ATCC14468 with MIC values of 12.5 and 7.8 μM, respectively. Antibacterial agent 81 can be used for the research of infection.
  • HY-128384
    Benzyldodecyldimethylammonium chloride dihydrate

    Bacterial Infection
    Benzyldodecyldimethylammonium chloride dihydrate is a quaternary ammonium compound (QAC) and can be used as a biocide to target antibiotic-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant (MDR) P. aeruginosa et. al. Benzyldodecyldimethylammonium chloride dihydrate, an antimicrobial agent, bacteriostatic or bactericidal properties depending on the concentration.
  • HY-B0974
    Methicillin sodium salt

    Meticillin sodium

    Bacterial Antibiotic Infection
    Methicillin sodium salt (Meticillin sodium) is a β-lactam, semi-synthetic antibiotic related to penicillin antibiotic. Methicillin sodium salt inhibits penicillin-binding proteins involved in the synthesis of peptidoglycan. Methicillin sodium salt inhibits S. aureus with a MIC value of 2.1 μg/mL. Methicillin sodium salt can be used for the research of inflammation.
  • HY-N7307
    Pachybasin

    Bacterial Infection
    Pachybasin is a major metabolite from culture broth of endophytic coelomyceteous AFKR-18 fungus. Pachybasin showes antimicrobial activities against E. coli, B. subtilis, M. luteus, S. cerevisiae, C. albicans, A. niger, and A. flavus, with MIC values of 64.0 μg/mL, and against S. aureus and F. oxysporum with MIC values of 32.0 and 16.0 μg/mL respectively.
  • HY-135969
    Glycol chitosan

    Bacterial Infection
    Glycol chitosan is a chitosan derivative with ethylene glycol branches. Glycol chitosan enhances membrane permeability and leadkage in Glycine max Harosoy 63W cells. Glycol chitosan is biocompatible and biodegradable. Glycol chitosan inhibits E. coli, S. aureus and S. enteritidis growths with MIC values of 4 μg/mL, 32 μg/mL and <0.5 μg/mL, respectively.
  • HY-128905
    MC-Val-Cit-PAB-dimethylDNA31

    Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus.
  • HY-B0975S
    Penicillin V-13C6 potassium

    Phenoxymethylpenicillin-13C6 potassium

    Bacterial Antibiotic Infection
    Penicillin V-13C6 (potassium) is the 13C6 labeled Penicillin V (potassium). Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis.
  • HY-P3328
    MDP1

    Bacterial Infection
    MDP1, a Melittin-derived peptide, alters the integrity of both Gram-positive and Gram-negative bacterial membranes and kills the bacteria via membrane damages. MDP1 has a high-antibacterial activity against multidrug resistant (MDR) and reference strains of S. aureus, E. coli, and P. aeruginosa.
  • HY-P3328A
    MDP1 acetate

    Bacterial Infection
    MDP1 acetate, a Melittin-derived peptide, alters the integrity of both Gram-positive and Gram-negative bacterial membranes and kills the bacteria via membrane damages. MDP1 acetate has a high-antibacterial activity against multidrug resistant (MDR) and reference strains of S. aureus, E. coli, and P. aeruginosa.
  • HY-N7118
    Clindamycin hydrochloride monohydrate

    Bacterial Antibiotic Infection Cancer
    Clindamycin hydrochloride monohydrate is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin hydrochloride monohydrate resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin hydrochloride monohydrate decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla).
  • HY-B0975AS
    Penicillin V-d5

    Bacterial Antibiotic Infection
    Penicillin V-d5 (Phenoxymethylpenicillin-d5) is the deuterium labeled Penicillin V. Penicillin V (Phenoxymethylpenicillin) is an orally active antibiotic. Penicillin V inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis.
  • HY-106410A
    Zabofloxacin hydrochloride

    DW-224a

    Bacterial Topoisomerase Antibiotic Infection
    Zabofloxacin hydrochloride (DW-224a) is a potent and seletive inhibitor of the bacterial type II and IV topoisomerases. Zabofloxacin hydrochloride has excellent activity against gram-positive pathogens including Steptococcus aureusStreptococcus pyogenes and S.pneumonia. Zabofloxacin hydrochloride is a novel fluoronaphthyridone quinolone that is considered as an alternative antibiotic for treatment of quinolone-susceptible (QSSP) and quinolone-resistant gonorrhea (QRSP).
  • HY-147531
    Antibacterial agent 106

    Bacterial Infection
    Antibacterial agent 106 (compound 8) is an orally active and potent antibacterial agent with antibiofilm activity. Antibacterial agent 106 shows potent antibacterial effect against multi-drug resistant (MDR)-Gram positive pathogens. Antibacterial agent 106 is highly effective in clearing 99.7% of the intracellular methicillin-resistant S. aureus (MRSA) harbored inside macrophages.
  • HY-106410
    Zabofloxacin

    DW-224a Free base

    Bacterial Topoisomerase Antibiotic Infection
    Zabofloxacin (DW-224a Free base) is a potent and seletive inhibitor of the bacterial type II and IV topoisomerases. Zabofloxacin has excellent activity against gram-positive pathogens including Steptococcus aureusStreptococcus pyogenes and S.pneumonia. Zabofloxacin is a novel fluoronaphthyridone quinolone that is considered as an alternative antibiotic for treatment of quinolone-susceptible (QSSP) and quinolone-resistant gonorrhea (QRSP).
  • HY-146098
    Antibacterial agent 105

    Bacterial Antibiotic Infection
    Antibacterial agent 105 (Compound 17) is a phenanthrolinic analog of quinolones show antibacterial activity against M. tuberculosis with antibacterial activity (MIC90=2.64 μM)。Antibacterial agent 105 exhibits antibacterial activities against different bacterial species with MIC90s of 11.18, 11.18,0.70,1.40,44.70, and 22.35 μM for M. smegmatis, M. aurum, M. marinum,BCG, E. aerogenes and S. aureus, respectively.
  • HY-146427
    Antifungal agent 29

    Fungal Infection
    Antifungal agent 29 (compound 9d) is a potent, selective and non-toxic antifungal agent. Antifungal agent 29 shows antifungal activity towards Cryptococcus neoformans (MIC ≤ 0.23 μM).
  • HY-N1654
    2',3'-Dehydrosalannol

    Bacterial Infection
    2',3'-Dehydrosalannol is a potent antibacterial agent. 2',3'-Dehydrosalannol shows antibacterial activity against K. pneumonia ATCC 13883, P. aeruginosa ATCC 27853, S. aureus ATCC 25922, E. coli ATCC 11775, and E. faecalis ATCC 10541, with MIC values of 0.78, 1.56, 1.56, 6.25, and 25 µg/mL, respectively.
  • HY-N7454
    Anhydroerythromycin A

    Bacterial Antibiotic Infection
    Anhydroerythromycin A is a degradation product of the macrolide antibiotic erythromycin. Anhydroerythromycin A is formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo. Anhydroerythromycin A is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively). Anhydroerythromycin A also inhibits steroid 6β-hydroxylase activity associated with the cytochrome P450 (CYP) isoform CYP3A in human liver microsomes.
  • HY-115990
    Topoisomerase IV inhibitor 1

    Topoisomerase Bacterial Infection
    Topoisomerase IV inhibitor 2 (compound 7d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC50s of 0.23 μM and 0.43 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 0.972 μM and 0.608 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively.
  • HY-115991
    Topoisomerase IV inhibitor 2

    Topoisomerase Bacterial Infection
    Topoisomerase IV inhibitor 2 (compound 5d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC50s of 0.35 μM and 0.55 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 1.985 μM and 0.744 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively.
  • HY-125728
    Micrococcin P1

    Bacterial Parasite HCV Infection
    Micrococcin P1 is a macrocyclic peptide antibiotic and is a potent hepatitis C virus (HCV) inhibitor with an EC50 range of 0.1-0.5 μM. Micrococcin P1 has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Micrococcin P1 against S. aureus 1974149, E. faecalis 1674621 and S. pyogenes 1744264 are 2 μg/mL, 1 μg/mL and 1 μg/mL, respectively. Micrococcin P1 is also a potent inhibitor of the malaria parasite Plasmodium falciparum.
  • HY-B1455
    Clindamycin

    Bacterial Antibiotic Parasite Infection Cancer
    Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria.
  • HY-10581AS
    Gatifloxacin-d3 hydrochloride

    AM-1155-d3 hydrochloride; BMS-206584-d3 hydrochloride; PD135432-d3 hydrochloride

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin-d3 (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
  • HY-B1916
    Acetylspiramycin

    Spiramycin B; Spiramycin II; Foromacidin B

    Antibiotic Bacterial Parasite Infection
    Acetylspiramycin (Spiramycin B; Spiramycin II; Foromacidin B) is a potent and orally active macrolide antibiotic produced by various Streptomyces species, an acetylated derivative of Spiramycin (HY-100593). Acetylspiramycin is an antimicrobial agent with activity against gram-positive organisms, including Streptococcus pyogenes, S. viridans, Corynebacterium diphtheriae and methicillin-sensitive Staphylococcus aureus. Acetylspiramycin is also a potent antiprotozoal agent that against parasitic infection caused by Cryptosporidium spp.
  • HY-N6686
    Virginiamycin M1

    Pristinamycin IIA; Ostreogrycin A

    Bacterial Antibiotic Infection
    Virginiamycin M1 (Pristinamycin IIA; Ostreogrycin A), produced by Streptomyces virginiae, is an polyunsaturated macrocyclic lactone antibiotic and acts as a component of Virginiamycin (HY-112665). Virginiamycin M1 alone is against Staphylococcus aureus with a MIC of 0.25 μg/mL. The combination of Virginiamycin M1 and Virginiamycin S1 (HY-N6680) is 0.125 μg/mL (MIC Value), which can improve the bactericidal effect 1-30 times.
  • HY-N0656A
    (+)-Usnic acid

    mTOR Bacterial Autophagy Cancer
    (+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of mTOR, and inhibits mTORC1/2 activity. (+)-Usnic acid inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer activity. (+)-Usnic acid possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium.
  • HY-B1455S
    Clindamycin-d3 hydrochloride

    Bacterial Antibiotic Parasite Infection
    Clindamycin-d3 hydrochloride is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria.
  • HY-B1455S1
    Clindamycin-13C,d3

    Bacterial Antibiotic Parasite Infection
    Clindamycin-13C,d3 is the 13C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria.